文献速递膀胱癌与上尿路尿路上皮癌

T1期高级别肿瘤的分子分型是否重要

Does it matter whether a T1 high-grade tumor is molecularly classified?
PubMed 文献 · Eur Urol Oncol · 2019-08-03

本文以一例58岁男性吸烟者为引,讨论T1期高级别膀胱肿瘤在治疗决策前是否需分子分型,还是仍仅依赖临床病理特征。患者初发左侧单发高级别乳头状肿瘤伴原位癌,行整块切除及4周复查电切无残留,接受卡介苗(BCG)灌注加维持治疗,9个月膀胱镜发现右侧T1b高级别肿瘤。文中讨论新病理方法可能帮助临床医生在膀胱切除与保留膀胱策略间安全决策。

要点

  • T1期高级别膀胱肿瘤的治疗决策目前仍主要依据临床病理特征。
  • 分子分型新方法可能帮助识别适合保留膀胱治疗的患者。
  • 原文以病例讨论形式提出分子分型是否影响治疗决策的问题。

核心结论

  • 原文讨论新病理方法可能帮助临床医生在膀胱切除与保留膀胱策略之间安全决策。

研究设计与样本

  • 原文为病例讨论,描述一例58岁男性吸烟者T1期高级别膀胱肿瘤的诊治经过。

主要发现

  • 患者初发左侧单发高级别乳头状肿瘤伴瘤周原位癌,膀胱外未见肿瘤。
  • 行整块切除,4周复查经尿道膀胱电切未见残留肿瘤。
  • 给予卡介苗(BCG)加维持治疗,9个月膀胱镜发现右侧T1b高级别肿瘤。
  • 原文讨论按标准临床标准对原发浅表浸润性肿瘤及9个月后相似复发进行归类。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 58-yr-old male, 20 pack-year smoker, with hypertension was diagnosed with a single left-side high-grade papillary tumor with peritumoral carcinoma in situ, but no tumor was visible outside the bladder. En bloc resection was performed, and repeat transurethral resection of the bladder at 4 wk found no residual tumor. He was prescribed bacillus Calmette-Guérin (BCG) plus maintenance therapy, and cystoscopy at 9 mo found a T1b high-grade tumor, this time right sided. Is it important that the tumor should be molecularly characterized before a treatment decision is made, or is clinicopathologic characterization still the only viable option at this time? PATIENT SUMMARY: We discussed how new methods in pathology may help us find molecular structures that would help clinicians decide safely between cystectomy and conservative bladder-sparing strategies. The primary superficially infiltrative tumor and its similar recurrence 9 mo later were categorized based on standard clinical criteria, but here we discuss whether recently discovered methods for defining the molecular structure of tumors could mean that more bladder-preserving treatments might be an option.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Stenzl A, McConkey D, Bellmunt J, et al. Does it matter whether a T1 high-grade tumor is molecularly classified? Eur Urol Oncol. 2019. PMID: 31383572. doi:10.1016/j.euo.2019.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。